AdaptHealth Corp. (NASDAQ:AHCO) Receives Consensus Rating of "Moderate Buy" from Brokerages

Key Points

• AdaptHealth Corp. (NASDAQ:AHCO) has received a consensus rating of "Moderate Buy" from six brokerages, with one analyst rating it a sell and five giving it buy ratings.
• The average 1-year target price for AdaptHealth's stock is $13.40, while its shares opened at $8.89 on Friday.
• Insider trading includes Director David Solomon Williams III selling 8,200 shares, representing a 14.08% decrease in his ownership of the stock.

Shares of AdaptHealth Corp. (NASDAQ:AHCO - Get Free Report) have been given a consensus rating of "Moderate Buy" by the six brokerages that are covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating and five have given a buy rating to the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $13.40.

A number of research analysts recently weighed in on AHCO shares. Zacks Research lowered shares of AdaptHealth from a "hold" rating to a "strong sell" rating in a research report on Friday, September 19th. Wall Street Zen raised shares of AdaptHealth from a "hold" rating to a "buy" rating in a research report on Saturday, August 9th.

AdaptHealth Stock Up 1.8%

AHCO opened at $8.89 on Friday. The company has a debt-to-equity ratio of 1.14, a current ratio of 1.06 and a quick ratio of 0.82. The company's 50-day moving average is $9.28 and its 200 day moving average is $9.14. AdaptHealth has a fifty-two week low of $7.11 and a fifty-two week high of $11.63. The firm has a market capitalization of $1.20 billion, a P/E ratio of 16.46, a PEG ratio of 0.99 and a beta of 1.59.

Insider Buying and Selling at AdaptHealth

In related news, Director David Solomon Williams III sold 8,200 shares of the firm's stock in a transaction dated Friday, August 22nd. The shares were sold at an average price of $9.73, for a total transaction of $79,786.00. Following the transaction, the director directly owned 50,045 shares of the company's stock, valued at $486,937.85. This trade represents a 14.08% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 1.55% of the stock is owned by insiders.

Institutional Trading of AdaptHealth

Several hedge funds have recently added to or reduced their stakes in AHCO. Nuveen Asset Management LLC raised its position in AdaptHealth by 27.9% in the fourth quarter. Nuveen Asset Management LLC now owns 316,108 shares of the company's stock worth $3,009,000 after acquiring an additional 69,050 shares during the period. ProShare Advisors LLC raised its position in AdaptHealth by 44.3% in the fourth quarter. ProShare Advisors LLC now owns 30,766 shares of the company's stock worth $293,000 after acquiring an additional 9,450 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in AdaptHealth by 21.8% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 197,901 shares of the company's stock worth $1,884,000 after acquiring an additional 35,431 shares during the period. Mackenzie Financial Corp raised its position in AdaptHealth by 111.8% in the fourth quarter. Mackenzie Financial Corp now owns 81,583 shares of the company's stock worth $777,000 after acquiring an additional 43,059 shares during the period. Finally, GAMMA Investing LLC raised its position in AdaptHealth by 2,883.7% in the first quarter. GAMMA Investing LLC now owns 81,007 shares of the company's stock worth $878,000 after acquiring an additional 78,292 shares during the period. Institutional investors own 82.67% of the company's stock.

AdaptHealth Company Profile

AdaptHealth Corp., together with its subsidiaries, sells home medical equipment (HME), medical supplies, and home and related services in the United States. The company provides sleep therapy equipment, supplies, and related services, such as CPAP and bi-PAP services to individuals suffering from obstructive sleep apnea; medical devices and supplies, including continuous glucose monitors and insulin pumps for the treatment of diabetes; HME to patients discharged from acute care and other facilities; oxygen and related chronic therapy services in the home; and other HME devices and supplies on behalf of chronically ill patients with wound care, urological, incontinence, ostomy, and nutritional supply needs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.